Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Seres Therapeutics Inc
MCRB
Healthcare
Biotechnology
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic...
Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MCRB)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Nov 22, 2024 4:00pm
Seres Therapeutics to Participate in Piper Sandler Healthcar
News; $MCRB Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceCAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live
...more
(271)
•••
Napcoo
X
View Profile
View Bullboard History
Comment by
Napcoo
on Mar 28, 2024 11:31pm
RE:Now it's time to accumulate @78 cents
Q4 earnings says as a result, we have confidence that we will ultimately achieve our goal of VOWST becoming a foundational therapy for our CDI, potentially reaching or surpassing the highest
...more
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company
posted Dec 21, 2024 9:00am by
Voyageur Pharmaceuticals Ltd
-
|
Voyageur is securing supply chains in North America for barium, iodine and fullerene drug development and is aiming to gain efficiencies in production of contrast media products. The company anticipates this LOI will expand Voyageur’s project portfolio and diversify the Company’s product mix. The global contrast media market is valued at $6.3 billion with GE HealthCare projecting it will double over the next decade. ...read more
(271)
•••
Napcoo
X
View Profile
View Bullboard History
Post by
Napcoo
on Mar 28, 2024 11:26pm
Now it's time to accumulate @78 cents
$225 mln due if target milestone reached for the $575 mln deal, $175 mln upfront, $125 mln FDA approved, latest updates to reach sales target in 2024, which 2024 financial year? https://www
...more
(0)
•••
IvanIvan
X
View Profile
View Bullboard History
Post by
IvanIvan
on Apr 27, 2023 3:34am
Price
In December 2020, when SER-109 passed phase 3, the price rose to $38. Expect it to be at that price again in a month. Analysts will increase the target price after FDA approval.
(8)
•••
hoffbag
X
View Profile
View Bullboard History
Post by
hoffbag
on Jan 15, 2023 2:06pm
Maybe a chance to accumulate
Below 5 again. Maybe right cap on approval is between 800 - 900 million?
(8)
•••
hoffbag
X
View Profile
View Bullboard History
Post by
hoffbag
on Oct 31, 2022 5:10pm
Popping now!
Target valuation getting closer.
(8)
•••
hoffbag
X
View Profile
View Bullboard History
Post by
hoffbag
on Sep 08, 2022 3:13pm
Patience cont….
Now over 6.
(8)
•••
hoffbag
X
View Profile
View Bullboard History
Post by
hoffbag
on Aug 19, 2022 7:17pm
Patience and intestinal fortitude
Now over 5.
(8)
•••
hoffbag
X
View Profile
View Bullboard History
Post by
hoffbag
on Jun 08, 2022 2:20pm
SER 109
The time has come. BLA approval has a higher probability. Potential multi-bagger. Last traded this on the run from 4 to 20 in 2020. Lets have a repeat please.
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Candlestick Patterns All Traders Should Look Out For
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Viva Gold Reports Strong Initial Assay Results for its Fall 2024 Drill Program at Tonopah Gold Project